CDSCO Halts Sun Pharma Eye-Drop Production at Assam Plant
Regulators have stopped Sun Pharma from making and selling eye-care drugs from its Assam plant over quality system failures, with 332 recalled batches under review.
Pharma
PopVax Launches RNA Foundry for Personalised Cancer Vaccines
Hyderabad biotech PopVax has launched the RNA Foundry with Stochastic Sciences to design and manufacture personalised mRNA cancer vaccines, with capacity for more than 100 patient-specific vaccines in the next 12 months.
Sun Pharma Q2 FY27: India Sales Up 17%, US Slips 8%
Sun Pharma’s Q2 FY27 revenue rose 11.9% to ₹16,198.7 crore on a 17.3% jump in India formulations, while US sales fell 8.3% and a one-time loss pulled reported profit down 32%.
USFDA Flags 11 Observations at Granules’ Gagillapur Plant
The USFDA issued a Form 483 with 11 observations to Granules India’s Gagillapur finished dosage plant, its first inspection since the February 2025 Warning Letter; the company says supply is unaffected.
Imported Drugs Now Need 12 Months of Shelf Life Under New Rule
India now requires imported medicines to have at least 12 months of shelf life left on arrival, replacing the 60% rule; biologics and radiopharmaceuticals keep a 60% test.
India Medicine Sales Grow 12% to ₹70,180 Crore in Sept Quarter
India’s medicine sales rose 12% to ₹70,180 crore in the September quarter, a fourth straight double-digit gain led by cardiac, diabetes and cancer drugs.
Sanofi India Q3 Profit Jumps 54% to ₹117 Crore as Insulin Grows 9% and Public Sector Sales Surge 85%; ₹75 Interim Dividend
Sanofi India’s Q3 2026 profit rose 53.6% to ₹117 crore on revenue of ₹491.7 crore, as its insulin portfolio grew 9% and public sector sales jumped 85% on new analogue accounts. EBITDA margin widened to 32.8% and the board declared a ₹75 interim dividend.
Sun Pharma’s ILUMYA Wins US FDA Approval for Psoriatic Arthritis, Extending IL-23 Biologic Beyond Plaque Psoriasis
The US FDA has approved Sun Pharma’s sBLA for ILUMYA (tildrakizumab-asmn) in adults with active psoriatic arthritis, backed by the Phase 3 INSPIRE-1 and INSPIRE-2 studies. The provider-administered IL-23 inhibitor, approved for plaque psoriasis since 2018, now addresses a US PsA population of about 2.4 million.
Alivus Life Sciences Q2 FY27 Profit Jumps 51% to Rs 197 Crore; CDMO Revenue Up 80% as Solapur API Site Nears Start
Alivus Life Sciences (formerly Glenmark Life Sciences) posted Q2 FY27 revenue of Rs 682 crore, up 16%, and PAT of Rs 197 crore, up 51.3%. Non-Glenmark sales rose 20.8% to 79% of revenue, CDMO revenue grew about 80% to Rs 50 crore, and Solapur Phase 1 goes live in Q3 FY27.
India’s Pharma Exports Rise 4.9% to $16.14 Billion in H1 FY27 as Europe, ASEAN Offset Softer US Shipments
India’s pharmaceutical exports grew 4.90% to USD 16.14 billion in April–September 2026, Pharmexcil data shows. Q2 exports rose 3.05% to USD 8.04 billion, Europe climbed 9.66% to USD 3.29 billion, ASEAN rose 21.54% and bulk drugs grew 12.07%, while US shipments moderated.
Strides Pharma Q2 FY27 Revenue Rises 17% to ₹1,430 Crore as Ex-US Markets Overtake US Business for the First Time
Strides Pharma Science grew Q2 FY27 revenue 17% to ₹1,429.7 crore. Ex-US markets rose 31% to ₹696 crore, passing the US business (₹686 crore, +9%) in quarterly revenue for the first time, while EBITDA crossed ₹250 crore and margins eased to 17.6%.
Senores Pharmaceuticals Plans ₹43 Crore Capacity Expansion Across US and India, Adds Prefilled Syringe Line
Senores Pharmaceuticals will expand capacity at its US subsidiary Havix from 1.2 billion to 2 billion units a year and at Apnar Pharma in India from 0.5 billion to 1.2 billion units, and add a 2.7 million-unit prefilled syringe line at Ratnatris, for an estimated ₹43 crore by March 2027.
Laurus Labs Q2 FY27 Profit Jumps 126% to ₹441 Crore as CDMO Revenue Surges 75%; Picks Up 60% Stake in Canada’s Galenvs
Laurus Labs reported Q2 FY27 net profit of ₹441 crore, up 126%, on revenue of ₹2,206 crore, as CDMO revenue rose 75% to ₹904 crore and EBITDA margin widened to 34.5%. The Hyderabad drugmaker also agreed to take a 60% stake in Montreal-based Galenvs Sciences to deepen its oligonucleotide capabilities.
